stemmacolore
Cerca

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
PH-L19TNFCCNU-02/20 (GLIOSTAR)
Codice EudraCT
2022-501822-39-00
Sponsor/Promotore
PHILOGEN S.P.A.
Tipologia
Sperimentale
Fase
I / II
Unità Operativa
Principal Investigator
Torna in alto